Seminars in Nuclear Medicine
Volume 33, Issue 2 , Pages 129-135 , April 2003

Applications of positron emission tomography in psychiatry

References 

  1. Arango V, Underwood MD, Mann JJ. Postmortem findings in suicide victims: Implications for in vivo studies. Ann NY Acad Sci: The Neurobiology of Suicide: From the Bench to the Clinic. 1997;836:269–287
  2. Farde L, Hall H, Ehrin E, et al.  Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science JI - Sci. 1986;231:258–261
  3. Seeman P, Kapur S. Schizophrenia: More dopamine, more D2 receptors. Proc Natt acad Aci USA. 2000;97:7673–7675
  4. Post RM, DeLisi LE, Holcomb HH, et al.  Glucose utilization in the temporal cortex of affectively ill patients: Positron emission tomography. Biol Psychiatr. 1987;22:545–553
  5. Buchsbaum MS, Kesslak JP, Lynch G, et al.  Temporal and hippocampal metabolic rate during an olfactory memory task assessed by positron emission tomography in patients with dementia of the Alzheimer type and controls. Preliminary studies. Arch Gen Psychiatry. 1991;48:840–847
  6. Mann JJ, Malone KM, Diehl DJ, et al.  Demonstration in vivo of reduced serotonin responsivity in the brain of untreated depressed patients. J Cerebr Blood Flow Metab. 1995;15:S94; (abstr)
  7. Delgado PL, Price LH, Miller HL, et al.  Serotonin and the neurobiology of depression: Effects of tryptophan depletion in drug-free depressed patients. Arch Gen Psychia. 1994;51:865–874
  8. Mayberg HS, Liotti M, Brannan SK, et al.  Reciprocal limbic-cortical function and negative mood: Converging PET findings in depression and normal sadness. Am Psychiatr. 1999;156:675–682
  9. Berman KF, Doran AR, Pickar D, et al.  Is the mechanism of prefrontal hypofunction in depression the same as in schizophrenia? Regional cerebral blood flow during cognitive activation. Br J Psychiatr. 1993;162:183–192
  10. Frith CD, Friston KJ, Liddle PF, et al.  Willed action and the prefrontal cortex in man: A study with PET. Proceed Royal Soc Lond B Biol Sci (London). 1991;244:241–246
  11. Soares JC, Mann JJ. The anatomy of mood disorders—review of structural neuroimaging studies [see comments]. Biol Psychiatr. 1997;41:86–106
  12. Soares JC, Mann JJ. The functional neuroanatomy of mood disorders. J Psychiatr Res. 1997;31:393–432
  13. Bechara A, Damasio H. Decision-making and addiction (part I): Impaired activation of somatic states in substance dependent individuals when pondering decisions with negative future consequences. Neuropsychologia. 2002;40:1675–1689
  14. Damasio H, Grabowski T, Frank R, et al.  The return of Phineas Gage et al: Clues about the brain from the skull of a famous patient. Science J1 -Sci. 1994;264:1102–1105
  15. Mann JJ, Malone KM, Diehl DJ, et al.  Demonstration in vivo of reduced serotonin responsivity in the brain of untreated depressed patients. Am J Psychiatr. 1996;153:174–182
  16. Drevets WC, Videen TO, Price JL, et al.  A functional anatomical study of unipolar depression. J Neurosci. 1992;12:3628–3641
  17. Botteron KN, Raichle ME, Drevets WC, et al.  Volumetric reduction in left subgenual prefrontal cortex in early onset depression. Biol Psychiatr. 2002;51:342–344
  18. Bremner JD, Vythilingam M, Vermetten E, et al.  Reduced volume of orbitofrontal cortex in major depression. Biol Psychiatr. 2002;51:273–279
  19. Nobler MS, Sackeim HA, Prohovnik I, et al.  Regional cerbral blood flow in mood disorders III. Effects of treatment and clinical response in depression and mania. Arch Gen Psychiatr. 1994;51:884–897
  20. Nobler MS, Oquendo MA, Kegeles LS, et al.  Decreased regional brain metabolism following electroconvulsive therapy. Am Psychiatr. 2001;158:305–308
  21. Myers JE, Mieczkowski TA, Perel J, et al.  Abnormal behavioral responses to fenfluramine in patients with affective and personality disorders: Correlation with increased serotonergic responsivity. Bio Psychiatr. 1994;35:112–120
  22. McBride PA, DeMeo MD, Sweeney JA, et al.  Neuroendocrine and behavioral responses to challenge with the indirect serotonin agonist dl-fenfluramine in adults with obsessive-compulsive disorder. Biol Psychiatr. 1992;31:19–34
  23. Magistretti PJ, Pellerin I. Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging. Philos Trans Roy Soc Lond B Biol Sci. 1999;354:1155–1163
  24. Shulman RG. Functional imaging studies: Linking mind and basic neuroscience. Am J Psychiatr. 2001;158:11–20
  25. Buchsbaum MS. Positron emission tomography in schizophrenia. In:  Meltzer HY editors. Psychopharmacology. The Third Generation of Progress. New York: Raven Press; 1987;p. 783–792
  26. Sedvall G. The current status of PET scanning with respect to schizophrenia. Neuropsychopharmacology. 1992;7:41–54
  27. Ingvar DH, Franzen G. Abnormalities of cerebral blood flow distribution in patients with chronic schizophrenia. Acta Psychiatr Scand. 1974;50:425–462
  28. Baxter LR. Phelps ME, Mazziotta JC, et al: Cerebral metabolic rates for glucose in mood disorders. Studies with positron emission tomography and fluorodeoxyglucose F 18. Arch Gen Psychiatr. 1985;42:441–447
  29. Baxter LR. Schwartz JM, Bergman KS, et al: Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive- compulsive disorder. Arch Gen Psychiatr. 1992;49:681–689
  30. Bench CJ, Friston KJ, Brown RG, et al.  The anatomy of melancholia—Focal abnormalities of cerebral blood flow in major depression. Psychol Med. 1992;22:607–615
  31. Sackeim HA, Prohovnik I, Moeller JR, et al.  Regional cerebral blood flow in mood disorders. I. Comparison of major depressives and normal controls at rest. Arch Psychiatr. 1990;47:60–70
  32. Frith CD, Friston KJ, Liddle PF, et al.  A PET study of word finding. 1991;29:1137–1148
  33. Lucki I. The spectrum of behaviors influenced by serotonin. Biol Psychiatr. 1998;44:151–162
  34. Mann JJ. Role of the serotonergic system in the pathogenesis of major depression and suicidal behavior. Neuropsychopharmacology. 1999;21:99S–105S
  35. Shaskan EG, Snyder SH. Kinetics of serotonin accumulation into slices from rat brain: Relationship to catecholamine uptake. J Pharmacol Exp Ther. 1970;175:404–718
  36. Soucy JP, Lafaille F, Lemoine P, et al.  Validation of the transporter ligand cyanoimipramine as a marker of serotonin innervation density in brain. J Nucl Med. 1994;35:1822–1830
  37. Ramamoorthy S, Blakely RD. Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. Science. 1999;285:746–763
  38. Mann JJ, Huang YY, Underwood MD, et al.  A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal-cortical binding in major depression and suicide. Arch Gen Psychiatry. 2000;57:729–838
  39. Arango V, Underwood MD, Boldrini M, et al.  Serotonin 1A receptors, serotonin transporter binding and serotonin transporter mRNA expression in the brainstem of depressed suicide victims. Neuropsychopharmacology. 2001;25:892–903
  40. Malison RT, Price LH, Berman R, et al.  Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatr. 1998;44:1090–1098
  41. Staley JK, Berman RM, Malison RT, et al.  Follow-up study of midbrain serotonin transporter binding in major depression as measured by [I-123]-beta-CIT SPECT. J Nucl Med. 1999;40:143P; (abstr)
  42. Willeit M, Praschak-Rieder N, Neumeister A, et al.  [123I]-beta-CIT SPECT imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder. Biol Psychiatr. 2000;47:482–489
  43. Meyer JH, Wilson AA, Ginovart N, et al.  Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: A [(11)C]DASB PET imaging study. Am J Psychiatr. 2001;158:1843–1849
  44. Ichimiya T, Suhara T, Sudo Y, et al.  Serotonin transporter binding in patients with mood disorders: a PET study with [11C](+)McN5652. Biol Psychiatr. 2002;51:715–722
  45. LeDoux JE. Emotional memory systems in the brain. Behav Brain Res. 1993;58:69–79
  46. Schneider F, Gur RE, Mozley LH, et al.  Mood effects on limbic blood flow correlate with emotional self-rating: A PET study with oxygen-15 labeled water. Psychiatr Res. 1995;61:265–283
  47. Sheline YI, Sanghavi M, Mintun MA, et al.  Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci. 1999;19:5034–5043
  48. Drevets WC, Videen TO, Price JL, et al.  A functional anatomical study of unipolar depression. Neurosci. 1992;12:3628–3641
  49. Abercrombie HC, Schaefer SM, Larson CL, et al.  Metabolic rate in the right amygdala predicts negative affect in depressed patients. Neuroreport. 1998;9:3301–3307
  50. Drevets WC. Prefrontal cortical-amygdalar metabolism in major depression. Ann N Y Acad Sci. 1999;877:614–637
  51. Drevets WC, Price JL, Bardgett ME, et al.  Glucose metabolism in the amygdala in depression: relationship to diagnostic subtype and plasma cortisol levels. Pharmacol Biochem Behav. 2002;71:431–477
  52. Boldrini M, Underwood MD, Hsiung S, et al.  Fewer serotoning transporter mRNA expressing neurons in the dorsal raphe nucleus of suicide victims. Soc Neurosci. 1999;25:1798; (abstr)
  53. Austin M, Whitehead R, Edgar C, et al.  Localized decrease in serotonin transporter-immunoreactive axons in the prefrontal cortex of depressed subjects committing suicide. Neuroscience. 2002;114:807–815
  54. Lesch KP, Mayer S, Disselkamp-Tietze J, et al.  5-HT1A receptor responsivity in unipolar depression: Evaluation of ipsapirone-induced ACTH and cortisol secretion in patients and controls. Biol Psychiatr. 1990;28:620–628
  55. Shiah IS, Yatham LN, Lam RW, et al.  Cortisol, hypothermic, and behavioral responses to ipsapirone in patients with bipolar depression and normal controls. Neuropsychobiology. 1998;38:6–12
  56. Moeller FG, Steinberg JL, Fulton M, et al.  A preliminary neuroendocrine study with buspirone in major depression. Neuropharmacology. 1994;10:75–83
  57. Mobayed M, Dinan TG. Buspirone/prolactin response in post head injury depression. J Affective Disord. 1990;19:237–241
  58. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression [see comments]. Arch Gen Psychiatr. 1997;54:597–606
  59. Sapolsky RM. The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol Psychiatr. 2000;48:755–765
  60. Lopez JF, Chalmers DT, Little KY, et al.  A.E. Bennett Research Award. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol Psychiatr. 1998;43:547–573
  61. Maines LW, Keck BJ, Smith JE, et al.  Corticosterone regulation of serotonin transporter and 5-HT1A receptor expression in the aging brain. Synapse. 1999;32:58–66
  62. Pike VW, McCarron JA, Lammertsma AA, et al.  Exquisite delineation of 5-HT1A receptors in human brain with PET and [carbonyl-11C]WAY-100635. Eur J Pharmacol. 1996;301:R5–R7
  63. Farde L, Ginovart N, Ito H, et al.  PET-characterization of [carbonyl-11C]WAY-100635 binding to 5-HT1A receptors in the primate brain. Psychopharmacology (Berl). 1997;133:196–202
  64. Parsey RV, Slifstein M, Hwang DR, et al.  Validation and reproducibility of measurement of 5-HT1A receptor parameters with [carbonyl-11C]WAY-100635 in humans: comparison of arterial and reference tissue input functions. J Cereb Blood Flow Metab. 2000;20:1111–1133
  65. Sargent PA, Kjaer KH, Bench CJ, et al.  Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatr. 2000;57:174–180
  66. Drevets WC, Frank E, Price JC, et al.  PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatr. 1999;46:1375–1387
  67. Farde L, Wiesel FA, Stone-Elander S, et al.  D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. Arch Gen Psychiatr. 1990;47:213–219
  68. Wong DF, Wagner H, Pearlson G, et al.  Dopamine receptor binding of C-11-3-N-methylspiperone in the caudate in schizophrenia and bipolar disorder: A preliminary report. Psychopharmacol Bull. 1985;21:595–598
  69. Breier A, Su TP, Saunders R, et al.  Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA. 1997;94:2569–2574
  70. Nordstrim A-L, Farde L, Wiesel F-A, et al.  Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients. Biol Psychiatr. 1993;33:227–235
  71. Martinez D, Mawlawi O, Hwang D, et al.  Positron emission tomography study of pindolol occupancy of 5-HT(1A) receptors in humans: Preliminary analyses. Nucl Med Biol. 2000;27:523–527
  72. Martinez D, Hwang D, Mawlawi O, et al.  Differential occupancy of somatodendritic and postsynaptic 5HT(1A) receptors by pindolol: a dose-occupancy study with [11C]WAY 100635 and positron emission tomography in humans. Neuropsychopharmacology. 2001;24:209–229
  73. Rabiner EA, Bhagwagar Z, Gunn RN, et al.  Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low. Am J Psychiatr. 2001;158:2080–2082
  74. Sargent PA, Kjaer KH, Bench CJ, et al.  Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635. Effects of depression and antidepressant treatment. Arch General Psychiatr. 2000;57:174–180
  75. Owens MJ, Knight DL, Nemeroff CB. Paroxetine binding to the rat norepinephrine transporter in vivo. Biol Psychiatr. 2000;47:842–845

☆ Address reprint requests to J. John Mann M.D., Department of Neuroscience, New York State Psychiatric Institute, 1051 Riverside Drive, Box #42, New York, NY 10032.

☆☆ 0001-2998/03/3302/0005$30.00/0

PII: S0001-2998(03)70017-8

doi: 10.1053/snuc.2003.127302

Seminars in Nuclear Medicine
Volume 33, Issue 2 , Pages 129-135 , April 2003

Article Tools